Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Traws Pharma (TRAW) just unveiled an announcement.
Steven M. Fruchtman has stepped down as President and Chief Scientific Officer of Traws Pharma, citing “good reason” and expecting severance pay per his employment terms, especially in light of a change in control. However, the company’s board disagrees with his interpretation and believes no severance is owed. Meanwhile, Victor Moyo remains the Chief Medical Officer for Oncology at Traws Pharma.
For a thorough assessment of TRAW stock, go to TipRanks’ Stock Analysis page.